← board
GLUE
Monte Rosa Therapeutics, Incdistress 4/10 · elevated risk$23.44-1%today-7% from 52w high
Oncology 1
Lead: Healthy Volunteers · target HER2
Revenue
pre-revenue
Liquidity
$160M
Runway
10.9 yrs
Shares 1y
+37%
Price & events
+1.8% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.5%
1D
+1.2%
1W
+13.2%
1M
+16.2%
3M
+2.6%
6M
+293.3%
1Y
+414.0%
2Y
+0.3%
5Y
+10.7%
All
Overview
- Market Cap
- $1.98B
- Volume
- 27.09K
- 52 Week Range
- $4.19 – $25.31
- Total Shares
- 84.48M
- Float Shares
- 54.02M
- Short %
- 22.41%
- % Held by Insiders
- 0.58%
- % Held by Institutions
- 113.25%
- RVOL
- 0.02x
- Beta
- 1.56
Pipeline stages · 1 programs
MRT-8102
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 3 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-07 | Phase 1 | MRT-8102 | Healthy Volunteers, Elevated CRP | 100 | active not recruiting |
| 2026-05 | Phase 1/2 | Oral MRT-2359 | NSCLC, SCLC, High Grade Neuroendocrine Cancer, DLBCL, L-MYC and N-MYC Amplified Solid Tumors, NSCLC With High or Low L-MYC or N-MYC Expression, HR-positive, HER2-negative Breast Cancer, Prostate Cancer | 174 | active not recruiting |
| 2025-04-10 | Phase 1 | MRT-6160 | Healthy Volunteers | 108 | completed |
Catalyst news & presentations · 17
- 2026Guided 40%regulatory submissionFiled (NDA/BLA)next-generation NEK7-directed MGD · Submit IND applicationSEC 8-K
- H2 2026Guided 55%conferencedata presentationsecondaryMRT-8102 · Share data from GFORCE-1 studySEC 8-K
- 2026Guided 40%regulatory submissionFiled (NDA/BLA)second-generation NEK7-directed MGD · IND application for NEK7-directed MGD with enhanced CNS penetrationSEC 8-K
- 2026Guided 40%regulatory submissionFiled (NDA/BLA)CDK2 and/or cyclin E1-directed MGD · Submit IND applicationSEC 8-K
- 2026Guided 40%trial initiationsecondaryPhase 2MRT-8102 · Initiate Phase 2 GFORCE-2 studySEC 8-K
- 2026Guided 40%conferencedata presentationsecondaryCCNE1-directed molecular glue degrader · Presents preclinical data at the AACR Annual Meeting 2026PR wire
- 2026Guided 40%regulatory submissionFiled (NDA/BLA)NEK7 program (CNS-penetrant) · IND submission for second-generation CNS-penetrant NEK7 program.SEC 8-K
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
- early 2026conferencedata presentationsecondaryPhase 1MRT-8102 · Interim Phase 1 data for MRT-8102SEC 8-K
- February 2026conferencedata presentationsecondaryPhase 1/2MRT-2359 · Updated Phase 1/2 data at ASCO GU SymposiumSEC 8-K
- 2026-01-08partnershipUnderwritten public offering priced at $24/share and pre-funded warrants at $23.9999SEC 8-K
- 2026-01-07withdrawalTerminated the ATM prospectus; no further sales under the Sales Agreement without a new prospectus.SEC 8-K
- H2 2025readoutPhase 1/2MRT-2359 · Additional Phase 1/2 results expected in second half of 2025.SEC 8-K
- 2025-09-13partnershipCollaboration with Novartis for immune-mediated disease degrader programsSEC 8-K
- H1 2025regulatory submissionFiled (NDA/BLA)MRT-8102 · IND filing for MRT-8102SEC 8-K
- Q1 2025readoutPhase 1MRT-6160 · Initial clinical data from Phase 1 SAD/MAD studySEC 8-K
- 2024-10-25partnershipMRT-6160 · Global exclusive license to develop, manufacture, and commercialize VAV1 MGDs, including MRT-6160.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $33 (+41% upside) · 6 analysts
- 2026-06-30GuggenheimBuy
- 2026-05-11JP MorganOverweight
- 2026-03-18GuggenheimBuy
- 2026-03-18Wells FargoOverweight
- 2026-01-14Piper SandlerOverweight
- 2026-01-08Wells FargoOverweight
Competitors — HER2
Recent news
- 2026-07-20Enterprise value to EBITDA forward of Monte Rosa Therapeutics, Inc. – NASDAQ:GLUE - TradingView
- 2026-07-20Have Insiders Sold Monte Rosa Therapeutics Shares Recently? - simplywall.st
- 2026-07-19Price to earnings forward of Monte Rosa Therapeutics, Inc. – NASDAQ:GLUE - TradingView
- 2026-07-17Insider Sell: Markus Warmuth Sells Shares of Monte Rosa Therapeutics Inc (GLUE) - GuruFocus
- 2026-07-17Insider Sell: Markus Warmuth Sells Shares of Monte Rosa Therapeu - GuruFocus
- 2026-07-17Insider Sell: Markus Warmuth Sells Shares of Monte Rosa Therapeu - GuruFocus
- 2026-07-17Monte Rosa Therapeutics (GLUE) CEO sells 9,500 shares at about $23 each - Stock Titan
- 2026-07-17Monte Rosa CEO Markus Warmuth sells 9,500 shares worth $220,219.55 - Bitget
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.